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Preface 
Student’s role 
My role included formulation of the study question, treatment of patients contained 
within the database, collection of patient data, submission to the institutional ethics 
committee, requesting data from the corresponding data managers, merging and 
cleaning data sets, literature review to determine appropriate variables for 
multivariable models and to determine the optimal methodology to answer the study 
question. I performed the data analysis and modelling, model assessment, model 
diagnostics and clinical interpretation of the analysis. Following this I wrote the 
project report in the form of a scientific manuscript suitable for a peer-reviewed 
journal submission. 
 
Reflection on learning 
 
Communication skills and work planning: 
The primary communication challenges in this project were crossing the barriers 
between clinician and statistician. I needed to describe the clinical research question 
and background to my statistical supervisor and write the manuscript in a manner 
suitable for a clinical journal appropriate for a non-statistician to read. 
Communicating the research question to my supervisor was relatively straight-
forward, and my supervisor was very helpful in developing the approach to analysis 
and presentation of results. However, preparing this project for a clinical journal so 
that the results not only could be understood by a non-statistician but also be of 
interest was challenging.  The central nature of the statistical analysis to the results 
and discussion differed from prior research projects I have undertaken.  
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As a full-time surgeon, planning meetings with my statistical supervisor was 
challenging. The flexibility of my supervisor enabled us to meet on multiple 
occasions to discuss the general research aims and methodology. We used email as 
the primary method of assessing progress and discussion of specific statistical 
techniques, their application and presentation in this project. Whilst in principle 
clinical research is encouraged, there is no practical support from hospitals to 
facilitate this type of research undertaken by surgeons. Therefore this project was 
undertaken primarily on nights and weekends amidst a busy work schedule trying to 
balance family commitments. Delays in receiving institutional ethics approval made 
commencing this project difficult even though the data was contained within 
established databases. These constraints mean that efficient time management, 
planning and flexibility were essential to meet project deadlines. 
 
Statistical principles and methods: 
This project has expanded my knowledge in a number of areas related to survival 
analysis. In particular, multiple texts and articles were consulted to begin to 
understand the appropriate application of frailty models even though this had been 
covered to some degree in the survival analysis unit of study.  Determining whether 
clustering was appropriate outside of repeated events analysis was a major issue of 
concern. The use of failure rates was a familiar concept but not a technique that I had 
previously encountered during the survival analysis unit. This provided a useful 
graphical adjunct to the usual Kaplan Meier survival curves and was easier to apply 
confidence intervals where the Kaplan Meier curves became too cluttered when 
confidence intervals were included. My statistical supervisor suggested using lift 
5 
 
curves to compare the staging systems ability to capture deaths due to disease. I was 
not familiar with the use of lift curves for other statistical models and do not believe 
that this has been applied to survival analysis previously. The alternative of a time-
adjusted receiver operator curve was also considered. The first decision to be made 
was whether raw stage should be used to rank patients or whether this should be based 
on an adjusted hazard coefficient. In the end I decided to include both. The second 
problem was that using death due to disease alone did not take into consideration that 
a death after a shorter period of time implies a worse outcome than death after a long 
period of time. To try to account for this, which is critical in most time to event 
analyses, I decided to weight death inversely by the time to death from treatment. As 
there was no literature on the use of lift curves for survival analysis, I could not be 
sure whether this was a valid approach. 
 
Apart from these specific statistical techniques, a major challenge for this project was 
deciding what criteria should be used to compare the staging systems. A literature 
review was performed which was helpful to determine the broad criteria. The Cox 
proportional hazards model does not allow assessment of all of the predetermined 
criteria, however the models were helpful in assessing whether staging systems are 
monotonic and linear in terms of increasing risk with increasing stage. Deciding 
whether the staging systems should be assessed as raw or adjusted variables was also 
challenging since there are differing arguments for either approach. To try and 
overcome this, the final decision was made to assess the staging systems as both raw 
and after adjusting for appropriate covariates. 
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The statistical methods applied in this project were variable exploration and 
distribution, univariable comparisons using Kaplan-Meier survival estimates and the 
Log-rank test, applying the Cox proportional hazards model for multivariable 
comparisons. Within the Cox models the important principles included appropriate 
selection of covariates, assessment of the proportional hazards assumptions, 
assessment of linearity assumptions for continuous variables and appropriate 
transformations, assessment of potential significant interactions, assessment of 
influential outliers and consideration of frailty models. 
 
Statistical computing: 
The data was extracted from Microsoft excel and SPSS databases and imported to 
Stata version 11 for analysis. This provided an opportunity to improve my knowledge 
of Stata data cleaning, manipulation, analysis and generation of appropriate graphs. 
 
Teamwork 
Communication with other team members 
As I was responsible for the majority of the project there was very little teamwork 
required for this project other than discussion with my supervisor as discussed above. 
The data was sourced from two different data managers and after identification of 
potential influential outliers, I consulted the respective clinician to confirm the 
veracity of the data. 
 
Working within timelines: 
A set timeline and schedule was not created for this project. Since there were no other 
clinicians or statisticians directly involved with this project, I was not dependent on 
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others performing analyses or review of the analysis before proceeding. Analyses 
were performed on a weekly basis followed by presentation of interim results to the 
statistical supervisor and email discussion.  
 
Ethical considerations 
The data was de-identified and databases are maintained in a secure environment. 
Patients give consent for their data to be collected and added to the database. As I was 
not privy to any identifying variables, the only patient confidentiality issue arose 
when potential outliers were identified. This was managed by using database codes 
rather than requesting names or medical record numbers from the data managers. An 
alternative issue arose when one of the interim models suggested that patient 
outcomes were better at one institution compared to the other. Reporting this sort of 
information is associated with a myriad of concerns ranging from clinician ire to 
patient distress over where they were treated. Furthermore, this analysis demonstrated 
how easily introduction of an additional variable (in this case an interaction term) can 
change the interpretation of the results. Comparing outcomes between treating 
institutions or clinicians requires complex multilevel modelling and close scrutiny of 
both the results and their interpretation is essential before presentation. 
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Front Sheet 
Title  
A comparison of the 7
th
 edition American Joint Committee on Cancer (AJCC) and 
N1S3 nodal staging systems for metastatic cutaneous squamous cell carcinoma 
Location 
This project combined data from the Sydney Head and Neck Cancer Institute 
(SHNCI) and Westmead Head and Neck Cancer Centre (WHNCC) databases.  
Dates 
March – June 2011 
Context 
This project utilises data from two Australian cancer centres, one of which is the 
SHNCI, Royal Prince Alfred Hospital where I currently practice as a Head and Neck 
oncologic and reconstructive surgeon. Metastatic cutaneous cancer is a common 
condition encountered within Australia but is relatively uncommon in many other 
parts of the world. Until recently, nodal metastases were not given any prognostic 
stratification within the AJCC TNM staging system other than being present (N1) or 
absent (N0). The latest (7
th
) edition of the AJCC staging manual introduced complex 
nodal staging criteria in line with mucosal cancer of the Head and Neck. This was in 
response to a number of alternative staging systems recently published, some of 
which originated from the SHNCI. Australian cancer centres are in a unique position 
to examine whether the current AJCC staging system is an advance in the optimal 
staging of this malignancy. 
Contribution of student 
 Contributed to management of patients and collection of data 
pertaining to subjects within the SHNCI database 
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 Formulation of study aims and hypotheses, literature review and 
determination of appropriate confounding variables 
 Obtained data from data managers of respective cancer centres 
 Merged and cleaned data sets 
 Created staging variables for data set, Data exploration and description 
 Univariable comparisons and survival curves to determine variables for 
multivariable models. Comparison of failure rates. 
 Creation of multivariable models and predicted survival curves 
 Model diagnostics and examination of outliers 
 Under direction of statistic supervisor – creation of lift curves to 
compare performance of staging systems 
 Discussion with supervisor regarding statistical methods 
Statistical issues 
 Determining methodology to compare staging systems 
 Univariable survival analysis 
 Selection of appropriate variables for multivariable models 
 Multivariable model diagnostics and testing model assumptions 
 Exploration of potential frailty models 
 Understanding use of lift curves for assessing staging systems 
efficiency and application of lift curves to survival analysis 
Student declaration 
I declare this project is evidence of my own work, with direction and assistance 
provided by my project supervisor. This work has not been previously submitted for 
academic credit. 
…………………………………………………………….. Jonathan Clark 
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A comparison of the 7
th
 edition American Joint Committee on Cancer (AJCC) 
and N1S3 nodal staging systems for metastatic cutaneous squamous cell 
carcinoma 
 
Abstract 
Background: The American Joint Committee on Cancer (AJCC) substantially 
changed the staging of cutaneous squamous cell carcinoma (cSCC) in the 7
th
 edition 
of its staging manual. We aim to compare the 7
th
 edition AJCC staging of nodal 
metastases from cSCC with the ‘N1S3’ staging system. 
Methods: Analysis of 603 patients from two prospective cancer centre databases. 
Multivariable analysis was performed using a Cox proportional hazards model 
adjusting for the effect of immunosuppression, treating institution, adjuvant 
radiotherapy, nodal margins and extracapsular spread. Criteria used for comparing 
staging systems were distribution of patients, stratification of patients according to 
risk of death from cSCC and model performance. 
Results: The N1S3 staging system functioned well in terms of distribution and 
stratification of patients. The distribution of patients within the AJCC staging system 
was problematic with three groups (N2a, N2c and N3) containing less than 10% of 
patients without any prognostic relevance. Stratification of patients within the AJCC 
staging system was poor in terms of monotonicity (N2c) and distinctiveness (N2a). 
The performance of the AJCC and N1S3 staging systems was similar despite the 
AJCC staging being more complex. 
Conclusion: The N1S3 staging system is preferred on the grounds of distribution, 
stratification and parsimony.  
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Introduction 
Non-melanoma skin cancer (NMSC) is the most common malignancy in Australia 
and the majority of NMSCs occur on sun exposed regions, such as the head and neck.  
Cutaneous squamous cell carcinoma (cSCC) constitute 25% of NMSC and the 
incidence directly relates to proximity to the equator, ranging from 16/100,000/year in 
central Europe to 300/100,000/year in Australia[1].
  
Within Australia, the highest 
incidence is seen in Northern Queensland, where the annual rate exceeds 
1300/100,000 males[2, 3].
 
Despite the frequency of cSCC, nodal metastases occur in 
less than 5% of patients [3, 4] and there are relatively few studies on metastatic cSCC 
of the head and neck with large enough samples to power reliable conclusions about 
the behaviour of this disease. 
 
Head and Neck mucosal SCC (mSCC) is less common than cSCC in most countries, 
particularly Australia, but mSCC exhibits a much greater propensity for developing 
nodal metastases. In 1977 the American Joint Committee on Cancer (AJCC) 
introduced a staging system for mucosal cancer in the first edition of its staging 
manual that stratifies patients according to the estimated to the risk of death from 
nodal metastases (N stage) [5] and this has been modified over time. Currently, nodal 
metastases from mSCC are divided into three main groups (N1, N2 and N3) on the 
basis of the size and number of lymph nodes involved. N2 is further sub-divided into 
three groups (N2a, N2b and N2c) on the basis of lymph node number and their 
laterality (side of the neck) giving a total of six groups including N0, which denotes 
the absence of nodal metastases. In contrast, until recently nodal metastases from 
cSCC have been divided into only two groups by the AJCC: N0 in patients with no 
nodal metastases and N1 in patients with nodal metastases.  
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The discrepancy between mucosal and cutaneous SCC staging systems prompted 
several alternative staging systems for cSCC to be evaluated [6-10]. Most of these 
alternative staging systems have stratified nodal metastases by the size and number of 
lymph node metastases in a similar fashion to mSCC. The most recent alternative 
staging system, called “N1S3” proposed by Forest et al [7] was published prior to 
the7th edition of the AJCC staging manual. It is relatively simple, allocating all single 
nodal metastases less than (or equal to) 3cm as nodal stage I, multiple nodes less than 
(or equal to) 3cm or single nodes greater than 3cm as nodal stage II and multiple 
nodes with at least one node greater than 3cm as stage III (Table 1). 
 
Table 1. 
N1S3 Staging system of nodal metastases for cutaneous squamous cell carcinoma 
 
  
I Single node measuring ≤ 3 cm in diameter 
 
II Single node measuring > 3 cm or multiple nodes  3 cm 
 
III Multiple nodes measuring > 3 cm in diameter 
 
 
 
In response to increasing literature suggesting the need for a more complex staging 
system for cSCC, the AJCC revised the TNM staging of cSCC in the 7
th
 edition of its 
staging manual[11] by adopting the same nodal (N) staging as that used for mSCC 
(Table 2). The advantages of using an established staging system are obvious, in 
terms of simplicity and ready acceptance due to familiarity[12]. However, the new 
staging system has not been evaluated previously. Its validity is questionable since 
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some components such as the laterality of lymph nodes (N2c) are not supported by 
any existing studies. 
 
Table 2. 
Nodal Staging of Mucosal and Cutaneous Squamous Cell Carcinoma from the 
7
th
 Edition of AJCC TNM Staging Manual 
 
  
N1 Single ipsilateral node ≤ 3cm in greatest dimension 
 
N2a 
 
Single ipsilateral node > 3cm, ≤ 6 cm in greatest dimension. 
 
N2b 
 
Multiple ipsilateral nodes ≤ 6 cm in greatest dimension 
 
N2c 
 
Bilateral or contralateral nodes, ≤ 6 cm in greatest dimension 
 
N3 
 
 
Any node > 6cm in greatest dimension 
 
 
There is minimal literature regarding what constitutes a good staging system for 
cancer and what criteria should be used to determine if one staging system is superior 
to another. Staging systems such as the AJCC TNM system have evolved over time to 
become a complex mix of anatomic disease extent, tumour grade and other prognostic 
factors. In many cancers, disease extent accounts for only a modest proportion of the 
variation in survival observed. In some tumours, disease extent has very limited 
prognostic value. For example, prognosis in papillary thyroid cancer is highly 
dependent on patient age and in patients under the age of 45 years, nodal metastases 
have minimal impact on survival and the presence of distant metastases is only 
considered to be stage II disease[13]. Despite this, within each T or N group an 
increasing number should correlate with worse prognosis rather than just depicting the 
anatomic extent of disease. The AJCC staging manuals state that the goal of cancer 
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staging is to group cancer characteristics for which patient survival differs between 
groups (distinctiveness), consistently decreases with increasing stage group 
(monotonicity), and is similar within a group (homogeneity) [14-16]. This is intended 
to be applied to the overall stage (I – IV) but the concepts of distinctiveness and 
monotonicity should apply within the T and N stages also. Distinctive groups should 
be clinically useful by avoiding stages that are rarely or too frequently applied and the 
monotonic decrease in survival should be sufficiently different as to be clinically 
relevant. Furthermore staging systems should not be unnecessarily complex and 
therefore the concept of parsimony should also apply. 
 
The primary aim of this study is to compare the 7
th
 edition AJCC TNM staging of 
nodal metastases in patients with cSCC with that of the N1S3 staging system. The 
criteria used to compare these staging systems is their ability to stratify patients 
according to risk of death due to cSCC taking into consideration distinctiveness and 
monotonicity, appropriate distribution of patients and staging model performance. 
 
Methods 
After institutional ethics approval was obtained, data on patients with nodal 
metastases from cSCC of the head and neck was obtained from two Australian cancer 
centre prospective databases, the Sydney Head and Neck Cancer Institute (SHNCI) 
database and Westmead Head and Neck Cancer Centre (WHNCC) database. This is a 
retrospective analysis of the two combined datasets which includes 331 patients from 
WHNCC and 272 from the SHNCI, giving a total of 603 patients with sufficiently 
complete data treated with curative intent between 1980 and 2010. During this time, 
management of patients has not differed substantially with surgery remaining the 
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primary treatment modality. The routine use of adjuvant radiotherapy, however, has 
become more routine over this time-frame and the differing application of 
radiotherapy is potentially an important confounding factor. The role of chemotherapy 
remains unproven and has only been used in a negligible proportion of patients. All 
patients underwent surgery (parotidectomy and / or neck dissection) and median 
duration of follow-up of survivors was 2.5 years (range 0.1 – 17 years). Only 
variables considered important for analysis based on existing literature[10, 17-20] 
were obtained including maximal nodal diameter, number of involved lymph nodes, 
presence of extracapsular spread (ECS) of tumour in lymph nodes, location of 
involved lymph nodes, margin status of lymph nodes, administration of radiotherapy, 
dose of radiotherapy, gender, age and presence of major immunosuppression. The 
pathological number, size and location of lymph nodes were used to calculate the 
AJCC nodal (N) stage and N1S3 stage. A simplified N stage was also devised where 
all N2 patients were combined. For simplicity, Nx (eg. N2b) will refer to the AJCC N 
stage and N1S3-I, II, III will refer to the N1S3 stage. These clinicopathological 
variables are summarised in Table 3 according to Hospital. 
 
Statistical Analysis: 
Data was collated and filtered using Excel (Microsoft, USA) and SPSS version 17.0 
(IBM, USA). The data was then imported and merged using Stata version 11.1.  The 
end point for analysis was disease-specific survival and was calculated from the date 
of surgery to date of death from cSCC or last follow-up.  Patients who died from 
causes other than cSCC were censored at the time of death.  Less than 10% of any 
variable contained missing data and most variables were complete. Missing values 
were imputed using other available data without statistical modeling where possible 
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(for example maximal lymph node diameter was based on pathology reports but 
clinical measures were used where pathological data was absent). In the case of 
missing categorical data the variable was assumed to be absent (for example 
extracapsular spread and immunosuppression). Differences in survival were 
determined using the general log-rank test, log-rank test for trend and univariable Cox 
proportional hazards model analysis. Failure rates were estimated for each staging 
system and compared. Preselected covariates (radiotherapy, ECS, nodal margin, age, 
hospital, radiotherapy dose and immunosuppression) were included in a multivariable 
Cox proportional hazards model where N1S3 stage and AJCC stage were included as 
categorical variables to avoid assumptions regarding linearity and monotonicity 
allowing individual estimates of effects of the levels of the two staging systems. Age 
and radiotherapy dose were removed from the model as they did not significantly 
contribute to the model, despite transformation. A significant interaction between 
hospital and radiotherapy was identified and an interaction term was included. Due to 
dependence amongst subjects within hospitals, the model was adjusted by clustering 
by institutions. To assess stage system performance and monotonicity, the N1S3 and 
AJCC stages were included as continuous variables. Proportion of explained variation 
(PVE) (R
2
 and RD
2
) were calculated using Stata ado-files developed by Royston[21]. 
Survival curves were generated using the Kaplan-Meier method and also based on 
hazard estimates from the multivariable Cox regression models.  Lift curves were 
generated by ranking patients by their adjusted estimated risk of failure (exp(xjβx)) 
and plotting this against the proportion of patients who died from cSCC. Weighted lift 
curves were generated by ranking patients and plotting this against the proportion of 
deaths weighted by follow-up time (∑                             ). 
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Table 3.  
Clinicopathological data of patients with nodal metastases from cutaneous 
squamous cell carcinoma of the head and neck according to institution 
Variable SHNCI WHNCC Total 
N 272 331 603 
Age mean (SD) 72.4 (10.83) years 68.0 (12.41) years 70.0 (11.92) years 
Male:Female ratio 
(% male) 
240 : 32 
(88.2%) 
275 : 56 
(83.1%) 
525 : 88 
(85.4%) 
Duration of follow up  
median (range) 
1.7 years 
(0.1 – 13.7) 
3.8 years 
(0.1 – 17.6) 
2.5 years 
(0.1 – 17.6) 
Involved lymph nodes 
median (range) 
1 node 
(1 – 67) 
1 node 
(1 - 29) 
1 node 
(1 – 67) 
Largest metastatic node 
median (range) 
25 mm 
(5 – 100) 
23 mm 
(3 – 92) 
25 mm 
(3 – 100) 
Involved margin n (%) 71 (26.1%) 191 (57.7%) 262 (43.5%) 
ECS n (%) 138 (50.7%) 265 (80.1%) 403 (66.8%) 
RT n (%) 159 (58.7%) 296 (89.4%) 455 (75.6%) 
RT dose median (range) 54 (0 – 66) Gy 60 (0 – 74) Gy 60 (0 -74) Gy 
Immunosuppression n (%) 4 (1.5%) 22 (6.7%) 26 (4.3%) 
AJCC N stage n (%) 
 N1 
 N2a  
 N2b 
 N2c 
 N3 
 
121 (44.5%) 
25 (9.2%) 
97 (35.7%) 
2 (0.7%) 
27 (9.9%) 
 
133 (40.2%) 
33 (10.0%) 
145 (43.8%) 
10 (3.0%) 
10 (3.0%) 
 
254 (42.1%) 
58 (9.6%) 
242 (40.1%) 
12 (2.0%) 
37 (6.1%) 
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Variable SHNCI WHNCC Total 
N1S3 stage n (%) 
 I 
 II 
 III 
 
121 (44.5%) 
123 (45.2%) 
28 (10.3%) 
 
135 (40.8%) 
137 (41.4%) 
59 (17.8%) 
 
256 (42.5%) 
260 (43.12%) 
87 (14.4%) 
Death from cSCC n 40 52 92 
Total Deaths n 63 117 180 
SHNCI – Sydney Head and Neck Cancer Institute 
WHNCC – Westmead Head and Neck Cancer Centre 
RT - Radiotherapy 
ECS – Extracapsular spread 
cSCC – cutaneous squamous cell carcinoma 
 
 
Figure 1 
Stage Shift from N1S3 to AJCC N Stage 
 
Legend 
Shift in Stage when applying the AJCC N stage to patients previously staged 
according to the N1S3 staging system. 
256 N1S3-I 
•254 N1 
•2 upstaged to 
N2c 
260 N1S3-II 
•58 N2a 
•171 N2b 
•7 N2c 
•24 Upstaged to 
N3 
87 N1S3-III 
•71 Downstaged to 
N2b 
•3 Downstaged to 
N2c 
•13 N3 
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Results 
Distribution by stage 
The distribution of patients by stage is shown in Table 3 and the shift in stage from 
N1S3 to AJCC is shown in Figure 1. Three groups from the AJCC staging system 
(N2a, N2c and N3) contained less than 10% of all patients implying that that these 
groups would be used infrequently. In particular the N2c group, which denotes 
contralateral or bilateral nodal metastases, contained only 12 patients (2%). In 
contrast the smallest N1S3 group, N1S3-III, contained 87 patients (14%). N1 and 
N1S3-I have very similar criteria, with the only difference being that the AJCC 
system requires the solitary involved lymph node to be ipsilateral to the primary 
tumour. Two patients were both N2c and N1S3-I. Figure 2 shows the number of 
deaths due to cSCC as a proportion of patients in each AJCC-N1S3 subgroup. Within 
each AJCC group, an increasing proportion of patients died with increasing N1S3 
sub-group. In particular, within N2c, only N1S3-III patients died. The converse was 
not observed within each N1S3 group. However, the proportion of N1S3-II/N2a 
patients who died was similar to N1S3-I patients. Despite any differences, the two 
staging systems were highly correlated (Spearman’s rho = 0.88, p< 0.0001; Kendall’s 
tau-b = 0.81 p < 0.0001). 
Figure 2  
 
D = 0/2
D = 0/7
D = 2/3
D = 28/254
D = 7/58
D = 30/171
D = 16/71
D = 4/24
D = 5/13
I
II
I
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S
3
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N1 N2a N2b N2c N3   
AJCC TNM Stage
Distribution of Patients and Mortality due to cSCC According to Stage
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Legend.  
Scatterplot of patients with metastatic cutaneous squamous cell carcinoma (cSCC) 
according to N1S3 stage versus AJCC N stage. The size of the balloons corresponds 
to the number of patients in each subgroup. D is the number of patients who died due 
to cSCC over the total number of patients in the subgroup. 
Table 4. 
Estimated two- and five-year disease specific survival and 95% confidence 
intervals according to stage 
Stage 2 Year DSS 95% CI 5 Year DSS 95% CI 
N1S3     
I 91% (85.7 – 94.1) 83% (75.1 – 88.0) 
II 85% (79.3 – 89.5) 78% (70.7 – 83.5) 
III 75% (62.7 – 83.3) 63% (48.6 – 74.3) 
AJCC N Stage     
N1 91% (85.6 – 94.1) 83% (75.0 – 88.0) 
N2a 86% (70.1 – 94.1) 79% (60.8 – 89.6) 
N2b 82% (75.9 – 86.9) 74% (66.2 – 80.2) 
N2c 81% (42.4 – 94.9) 81% (42.4 – 94.9) 
N3 80% (59.9 – 90.4) 65% (42.1 – 80.3) 
 
Stratification of risk by stage 
Kaplan-Meier disease specific survival curves generated according to staging system 
are shown in figures 3a – 3c with Kaplan-Meier estimates of two- and five-year 
disease specific survival are shown in Table 4. The curves demonstrate good 
stratification of survival according to N1S3 stage and there is strong evidence for a 
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difference in survivor functions across the groups (log-rank test χ2(2) =12.64, p = 
0.0018, log-rank test for trend χ2(1) = 11.89, p = 0.0006, deviation from linear trend 
Dχ2(1) =0.75, p = 0.61). The AJCC N2a-c groups did not stratify patients well, with 
the N2a and N2c curves overlapping with N1 and N2b. The difference across AJCC 
groups was not as strong (log-rank test χ2(4) =9.95, p = 0.041, log-rank test for trend 
χ2(1) = 9.44, p = 0.002) however there was no statistical deviation from linearity 
(deviation from linear trend Dχ2(2) =0.51, p = 0.23). When N2 patients were 
combined, the condensed N stage appeared to stratify patients in a similar fashion to 
the N1S3 staging system though due to the small number of events in the N3 group, 
the evidence for a difference across the groups was also not as strong (log-rank test 
χ2(2) =8.88, p = 0.012). After adjusting for the effect of immunosuppression, 
extracapsular spread, nodal margins, treating institution and radiotherapy using a Cox 
regression (no clustering) the N1S3 stage overall was significant as a categorical 
variable (W(2) =6.34, p = 0.04), however AJCC stage was not (W(4) =5.74, p = 0.22). 
 
Figure 3a 
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Figure 3b 
 
 
Figure 3c 
 
Legend 
Kaplan-Meier disease specific survival curves according to a) N1S3 stage, b) AJCC 
stage and c) AJCC stage with N2a-c combined. Numbers at risk at each time period 
are provided with the number of events in parentheses. Note the scale of the curves 
has been changed to aid identification of the different groups (lower limit 0.5). 
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Estimated failure rates for each staging system are shown in Figure 4. The point 
estimates of failure for N1S3 stage rise at each level without confidence intervals 
overlapping with the point estimate. In contrast, the N2c point estimate is less than 
N2b and the 95% confidence intervals for N2a, N2c and N3 are very broad due to the 
small number of events (death due to disease) in these groups. The estimated failure 
rates for N3 and N1S3-III are similar; however the confidence intervals for N3 are 
much broader. Comparisons between groups within staging systems were limited to 
two tests per staging system. There was weak evidence for a difference in survival 
between N1S3-I and N1S3-II (χ2(1) =3.30, p = 0.069) but was stronger between 
N1S3-II and N1S3-III (χ2(1) =5.86, p = 0.015). There was a difference in survival 
between N1 and N2 (combined N2a-c) (χ2(1) =8.77, p = 0.012) but not between N2 
(combined N2a-c) and N3 (χ2(1) = 1.04, p = 0.31). There was no difference between 
N2a, N2b or N2c. 
Figure 4 
 
Legend 
Comparison of failure rates (death from cSCC per Person-Year) for each staging 
system. Point estimates and 95% confidence intervals are provided for each stage. 
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Unadjusted hazard ratios (HR) and adjusted HRs in the final multivariable model are 
shown in Table 5 where the staging systems were fitted as categorical variables, 
therefore making no assumption about order or monotonicity. The effect of adjusting 
for other covariates was to reduce the hazard for both staging systems since there is 
considerable correlation between node size (an element in both staging systems) and 
both ECS and positive node margins. The estimated HR for N1S3-II and N1S3-III 
was 1.4 and 2.1, respectively, indicating a clinically useful, monotonic and linear 
increase in risk. The estimated HR for N2a, N2b, N2c and N3 was 1.1, 1.6, 1.4 and 
2.2 indicating that the increase in risk was neither clinically useful nor monotonic, in 
particular for N2a (similar to N1) and N2c (less than N2b) as illustrated in Figure 4. 
The increase in risk for N3 compared to N1S3-III was similar but included less 
patients in the highest risk group. The adjusted survival curves (Figure 5) generated 
from the regression models demonstrate poor discrimination between N1, N2a, N2b 
and N2c patients and also that N2c having improved survival compared to N2b. 
 
Staging System Performance 
The PVE (RD
2
) for the model incorporating N1S3 stage was 31.0%, which was 
similar to the model incorporating TNM stage at 30.6%. In both cases, the staging 
system alone explained only a small proportion of the total variation and although the 
point estimate for N1S3 (8.3%, 95% CI 1.58-18.50) was slightly higher than AJCC 
(6.7%, 95% CI 0.87 – 16.27) there was no statistically significant difference. The 
overall model fit for using Cox-Snell residuals and predictive power of the models as 
assed by Harrell’s C (0.72 v 0.71) and Somer’s D (0.42 v 0.41) was similar for both 
models as shown in Figure 6.  
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Table 5. 
Raw and Adjusted Effect of N1S3 and AJCC Staging Systems 
 Unadjusted Adjusted† 
N1S3 Model HR 95% CI p HR 95% CI p 
N1S3-II v I 1.5 0.95 - 2.49 0.078 1.4 1.21 - 1.65 <0.001 
N1S3-III v I 2.6 1.53 - 4.60 0.001 2.1 1.97 - 2.19 <0.001 
ECS    2.8 2.02 - 3.80 <0.001 
Immunosuppression    3.3 3.30 - 3.38 <0.001 
Involved Node Margin    2.0 1.73 - 2.34 <0.001 
Radiotherapy    0.06 0.06 - 0.07 <0.001 
Hospital    0.6 0.58 - 0.70 <0.001 
Interaction RT*Hospital    5.4 5.21 - 5.62 <0.001 
AJCC Model HR 95% CI p HR 95% CI p 
N2a v N1 1.2 0.54 – 2.85 0.61 1.1 0.62 - 2.02 0.71 
N2b v N1 1.8 1.13 – 2.90 0.013 1.6 0.98 - 2.57 <0.001 
N2c v N1 1.5 0.36 – 6.40 0.56 1.4 0.44 - 4.58 0.56 
N3 v N1 2.7 1.27 – 5.68 0.010 2.2 1.73 - 2.72 <0.001 
ECS    2.9 2.21 - 3.88 <0.001 
Immunosuppression    3.3 3.08 - 3.58 <0.001 
Involved Node Margin    2.0 1.77 - 2.22 <0.001 
Radiotherapy    0.06 0.05 - 0.07 <0.001 
Hospital    0.6 0.51 - 0.69 <0.001 
Interaction RT*Hospital    5.6 5.07 - 6.24 <0.001 
† Cox proportional hazards model Standard Errors adjusted for 2 clusters in Hospital 
HR – Hazard ratio. CI – confidence interval. RT - radiotherapy 
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Figure 5. 
 
 
Legend 
Predicted survival with other covariates (immunosuppression, involved node margin, 
radiotherapy, ECS and treating institution) fixed at their means using the N1S3 
staging system on the left and the AJCC staging system on the right. 
 
To assess the ability of the models to capture deaths due to cSCC, lift curves were 
generated by calculating the relative hazard (exp(xβx)) for each patient in the dataset 
based on the multivariable models, except AJCC and N1S3 stages were entered as 
continuous variables to force an assumption of increasing hazard with increasing 
stage. The relative hazard was ranked and plotted against the proportion of deaths 
(Figure 7a) and then weighted inversely by time to death (Figure 7b and 7c). All 
curves were significantly better than a random (uniform) distribution as indicated by 
the diagonal line where x% of deaths equals x% of patients (Kolmogorov-Smirnov 
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test p < 0.001).  The lift curves demonstrate similar capacity for both staging systems 
to capture deaths due to disease according to estimated hazard, suggesting that the 
AJCC staging system does not offer any increase in performance over the N1S3 
system despite being more complicated (Kolmogorov-Smirnov test p = 0.51 for 
unweighted data and p = 0.65 for weighted data).  When ranked according to raw 
stage (without adjusting for other covariates) and inversely weighted by time from 
treatment to death, the N1S3 stage appeared to perform marginally better than the 
AJCC stage as shown in Figure 7c (Kolmogorov-Smirnov test p = 0.06). 
 
Figure 6. 
 
 
 
Legend:  
Cox –Snell residuals (dashed lined) plotted against Nelson-Aelan cumulative hazard 
(solid line) for both staging systems. Note closer approximation of the two lines 
indicates better model fit. Harrell’s C and Somers’ D are measures of the ordinal 
predictive power of a model. 
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Figure 7a 
 
 
Figure 7b 
 
 
Figure 7c 
 
 
Legend 
Lift curves comparing N1S3 and AJCC TNM stage. Improved performance is 
indicated by greater area under the individual lift curves. No significant difference 
between curves was observed between staging systems.  
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Discussion 
The present study incorporates data from two Australian cancer centres and represents 
the largest study of metastatic cSCC to date. Given that only 15% of patients died 
from metastatic cSCC in this study, large cohorts are required to generate more 
complex models that can adjust for other clinicopathological variables in an attempt to 
determine the independent effect of stage alone. Whilst overall survival could be used 
to provide more events, in a sample with a mean age of 70 years, many patients will 
die from unrelated causes introducing more variability which cannot be explained 
without incorporating comorbidity data and other predictors of non-cancer mortality. 
Disease specific survival is favoured as an outcome measure in less aggressive 
malignancies, such as cSCC for similar reasons[15]. 
 
The AJCC staging manual for cancer intends for primary tumour (T), nodal (N) and 
distant metastatic (M) data to be incorporated together to generate an overall stage I – 
IV and therefore assessing N stage in isolation is somewhat dubious. However, 
important differences between cSCC and other malignancies, such as mSCC, are that 
nodal metastases do not frequently present concurrently with the primary tumour, and 
in most Australian patients there are multiple potential primary tumours over long 
time periods thus many patients would need to be excluded if primary tumour factors 
were to be included in the analysis.  Not only may it be impossible to determine the 
responsible primary tumour but it is unknown whether the primary factors are of any 
importance in patients with nodal metastases from cSCC. The metachronous nature of 
cSCC and our own (unpublished) data suggest that factors related to the nodal 
metastases are of principle importance. 
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To determine which staging system is more appropriate we have examined several 
criteria considered to be important for allocating stage to a malignancy. These include 
the distribution of patients by stage, stratification of patients by stage and 
performance of statistical models incorporating both the staging system alone and 
when combined with other potential confounding variables that may adjust the effect 
of stage. There is no uniform approach to how this should be undertaken, for example 
Brierley et al used a combination of the sum of observed deviations, mortality ratios 
and PVE to compare staging systems for thyroid cancer[22] where Wang et al used 
linear trend, likelihood ratio, and Akaike information criterion to comparing staging 
systems for gastric cancer[23]. Each approach has its own inherent limitations and it 
is difficult to know the whether any specific approach is superior to just looking at a 
Kaplan-Meier curve with confidence intervals. Whether raw or adjusted staging data 
should be used is contentious, therefore we have considered both. The adjusted effect 
is more useful in clinical practice where stage is rarely looked at in isolation, in 
particular adjusting for the effect of adjuvant treatment (not given to all patients) 
which alters the natural course of a disease is important. 
 
Distribution 
Although there is no stipulation that patients should be evenly distributed into staging 
groups, it is not beneficial to create groups that are rarely used unless they convey a 
unique clinical significance. Within the AJCC N stage there are three groups that 
apply to less than 10% of patients. This occurs mainly due to the separation of N2 into 
N2a, N2b and N2c paralleling the mSCC system, however in the case of cSCC the 
separation appears to create an irrelevant complexity. The strongest argument can be 
made against N2c which applies to only 2% of patients with metastatic cSCC in this 
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two-centre cohort and is estimated to have a better prognosis than N2b, though the 
confidence intervals are so large that the true effect could reasonably overlap with any 
group (42% – 95% two and five year disease specific survival). There does not appear 
to be any particular clinical significance attached to contralateral nodal metastases to 
warrant a distinct group. For example, a cSCC on the right midface with spread to the 
left submandibular lymph nodes would not be expected to carry a worse a prognosis 
than spread to the ipsilateral parotid nodes. The same could be argued for non-
lateralised mucosal cancer, of course, however the unpredictable nature of cutaneous 
sentinel nodes provides pathophysiological evidence as to why contralateral nodal 
metastases are unlikely to carry the same clinical significance as in mucosal cancer 
[24]. The N3 group was also relatively small (6%) and whether, it is more appropriate 
to have a higher proportion of patients in the most adverse prognostic group is 
arguable and depends on how the staging is applied. If the most adverse group will be 
given more aggressive therapy, then one may argue that more patients will be exposed 
to either the benefit or toxicity. It is important to mention, however, that staging 
systems such as the AJCC and N1S3 were not primarily designed to determine what 
therapy should be administered but rather to provide a common language for disease 
processes and to predict prognosis in terms of recurrence and survival[25]. Given that 
prognosis in N3 and N1S3-III was similar and N1S3-III still only represents 14% of 
patients, it is reasonable to favour using the larger group.  
 
Stratification 
The N1S3 staging system stratifies well in terms of discriminating risk of death and 
creating a monotonic and linear increase in risk with the adjusted hazard ratio for 
N1S3-I, II and III being 1.0, 1.4 and 2.1, respectively. This is easier to achieve in a 
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three-level than a five-level staging system and many of the problems associated with 
the AJCC staging system may be related to the small number of subjects / events 
within each group making the estimates unreliable. Despite this, the estimated hazards 
do not support the use of the current five-level staging system, particularly after 
adjusting for the effect of confounding variables. In particular the hazard ratio for N2a 
(1.1 adjusted, 1.2 raw) is too similar to that of N1 to be clinically useful. The 
problems with N2c have already been discussed. The increase in risk of death for the 
AJCC stage is not monotonic and thus does not conform to this basic staging 
principle. This is partially overcome in the 7
th
 edition of the AJCC staging system by 
grouping all N2 and N3 patients together as stage IV. However, this grouping seems 
inappropriate since N2 and N3 patients have an estimated 5 year disease specific 
survival 75% and 65%, respectively whereas no patient with distant metastases (M1) 
survived five years (0% 5 year DSS). 
 
Performance 
The evidence for a difference in survivor function for both the raw and adjusted N1S3 
stage was considerably stronger than for the corresponding AJCC stage. However, 
both the N1S3 and AJCC regression models performed similarly in terms of capturing 
deaths due to cSCC as shown by the lift curves and other predictive measures. 
Schemper argues that if the prognostic importance of factors is to be compared, then 
PVE is the most appropriate measure[26]. It is useful to note that the estimated 
variation in survival time explained by N1S3 alone (RD
2
 8.3%) is similar to AJCC 
stage (RD
2
 6.7%) as the confidence intervals broadly overlap. Given that the AJCC 
stage is considerably more complex (with two extra sub-categories) than the N1S3 
34 
 
stage, without any gain in performance, the empiric evidence would support a more 
parsimonious staging system. 
 
Limitations 
The retrospective nature of this study increases the potential for error and bias, 
however as the data was collected prospectively for the relevant databases (i.e. not 
specifically for this study) with less than 10% of data being imputed, this is 
minimized. The benefit of a prospective study to assess staging of patients is 
considerably less than that for an interventional study because confounding variables 
are invariably not evenly distributed either between or within staging systems and 
therefore one still needs to adjust for treatment and pathological variables regardless 
of the way in which data is collected. Even though radiotherapy is included as a 
variable in the model, there is limited ability to adjust for its effect and correlated 
confounders. This is clearly demonstrated by the interaction term between hospital 
and radiotherapy, where radiotherapy given in one institution has the opposite effect 
in the other. This can be explained by policy differences between institutions, 
correlation with other adverse factors and also because the effect is not based on 
‘intention to treat’ and therefore patients too sick to receive radiotherapy have an 
inflated adverse effect where the intention would have been to treat.  This may be 
overcome by a prospective study. The long time-frame of data collection over 30 
years also represents a problem due to changes in treatment philosophy and 
techniques. Whilst it is reasonable to assume that surgical techniques have not 
changed substantially, their application has become more standardised in terms of the 
extent of neck dissection. Radiotherapy techniques, on the other hand, have 
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undergone major changes in terms of dose and conformation. Furthermore, data 
supporting the use of adjuvant radiotherapy has led its routine application[10]. 
 
These staging systems only account for a small amount of the variability of patient 
outcomes (PVE < 10%) and even when other established variables are included, only 
one third of variability can be explained by the models. Therefore the importance of 
any particular prognostic variable could be argued to be minimal compared to the un-
explained variation. As the N1S3 staging system was developed from SHNCI 
patients, there are potential problems with over-fitting of data in this study. However, 
only node number and size were directly modelled (rather than N1S3 stage directly) 
and only one-third of the current sample was used for this modelling. The N1S3 stage 
was applied separately and validated on patients where the initial sample were 
excluded in the study by Forest et al [7], and this was repeated using a subset of 
patients as part of the current analysis. However, due to the low rate of disease-related 
death, the entire dataset was required to provide sufficient power for comparison of 
the staging systems. 
 
Recommendations 
There is no measure by which the AJCC staging system functions better than N1S3 
and in several categories it is worse despite being more complicated. Generally one 
would expect a more complex model to perform better than a simple model as it can 
use more variables to explain the variation observed. Whilst it is sensible and 
convenient to use an already established staging system, there is no evidence that 
cSCC should adopt the same staging as mSCC of the Head and Neck. In particular the 
N2a and N2c groups increase the complexity without any additional functionality.  A 
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number of alternatives would seem reasonable. Firstly the N1S3 staging system could 
be adopted, secondly the N2a, N2b and N2c groups could be combined to one N2 
group and lastly, based on the present data it would be practical to combine N2a with 
N1 and eliminate laterality of nodes (N2c). If the latter was done, this would result in 
the staging system summarised in Table 6 and would also require external validation. 
Kaplan-Meier disease specific survival curves according to this alternative TNM 
staging system is shown in Figure 8. 
 
Conclusion 
The 7
th
 edition of the AJCC staging manual for cSCC is a major advance over the 6
th
 
edition, however the AJCC staging system does not stage patients as well as the N1S3 
staging system despite being more complicated.   
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Table 6. 
Alternative TNM staging based on current data 
 
N1 
 
Single node ≤ 6cm in greatest dimension 
N2 Multiple nodes ≤3 cm in greatest dimension 
N3 
 
Multiple nodes > 3cm in greatest dimension or  
Any node > 6cm in greatest dimension 
 
Figure 8 
 
 
 
Legend 
Kaplan-Meier disease specific survival curves according to the alternative TNM stage 
described in Table 6. Note the scale of the curves has been changed to aid 
identification of the different groups (proportion surviving lower limit 0.5). 
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Statistical Appendix 
Normal Probability Plots of Continuous Variables 
Largest metastasis 
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Univariable survival comparisons using Kaplan-Meier Curves and Log-rank test  
Immunosuppression 
 
 
 
 
Log-rank test for equality of survivor 
functions 
 
      |   Events         Events 
imm   |  observed       expected 
------+------------------------- 
No    |        84          89.15 
yes   |         8           2.85 
------+------------------------- 
Total |        92          92.00 
 
            chi2(1) =       9.64 
            Pr>chi2 =     0.0019 
 
 
 
Gender 
  
 
 
 
 
 
Log-rank test for equality of survivor 
functions 
 
       |   Events         Events 
sex    |  observed       expected 
-------+------------------------- 
Male   |        80          78.04 
Female |        12          13.96 
-------+------------------------- 
Total  |        92          92.00 
 
             chi2(1) =       0.33 
             Pr>chi2 =     0.5679 
Extracapsular spread 
 
 
 
Radiotherapy Dose 
Test for trend of survivor functions 
 
               chi2(1) =       1.00 
                Pr>chi2 =     0.3174 
Age      
Test for trend of survivor functions 
 
           chi2(1) =       1.67 
            Pr>chi2 =     0.1969 
 
 
 
 
Log-rank test for equality of survivor 
functions 
 
           |   Events         Events 
extra_sp   |  observed       expected 
-----------+------------------------- 
No         |         1          10.94 
Yes        |        49          40.55 
Not stated |         2           0.51 
-----------+------------------------- 
Total      |        52          52.00 
 
                 chi2(2) =      15.17 
                 Pr>chi2 =     0.0005 
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Radiotherapy 
 
 
 
Node Margin 
 
 
 
 
 
 
Log-rank test for equality of survivor 
functions 
 
      |   Events         Events 
xrt   |  observed       expected 
------+------------------------- 
No    |        20          18.86 
Yes   |        72          73.14 
------+------------------------- 
Total |        92          92.00 
 
            chi2(1) =       0.09 
            Pr>chi2 =     0.7676 
 
 
 
 
 
 
 
Log-rank test for equality of survivor 
functions 
 
         |   Events         Events 
nod_marg |  observed       expected 
---------+------------------------- 
Clear    |        43          55.17 
Involved |        49          36.83 
---------+------------------------- 
Total    |        92          92.00 
 
               chi2(1) =       6.73 
               Pr>chi2 =     0.0095 
 
 
 
Hospital 
 
 
 
 
 
 
Log-rank test for equality of survivor 
functions 
 
         |   Events         Events 
Hospital |  observed       expected 
---------+------------------------- 
Westmead |        52          57.45 
RPAH     |        40          34.55 
---------+------------------------- 
Total    |        92          92.00 
 
               chi2(1) =       1.39 
               Pr>chi2 =     0.2389 
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Selection of covariates and model construction 
The model was constructed as per that described by Hosmer, Lemeshow and 
May[27]. As there were 92 deaths due to cSCC it was reasonable to include up to 9 
covariates. From previous literature it was felt that in addition to stage, radiotherapy 
and extracapsular spread (ECS) needed to be included in the model. Based on 
univariable comparisons immunosuppression and involved nodal margin were 
included. Age was considered, although it was felt that this was less important for 
disease specific rather than overall survival. It was also felt that there were likely to be 
institutional differences that needed to be considered and hence treating hospital 
would need to be included in the model. Only N1S3 models will be demonstrated in 
this section of the appendix. 
 
The initial model constructed (shown below) surprisingly showed that the treating 
institution was significant but radiotherapy was not. Age was not significant, however 
before removing age from the model the linearity assumption was assessed using 
martingale residuals and age was found to be approximately linear. Age was also 
dichotomised into greater and less than 70 years but was not significant. It was 
postulated that the reason why radiotherapy was not significant may be due to 
differing radiotherapy doses delivered. 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.235763   1.266913     3.00   0.003      1.50211    6.970303 
         xrt |    1.00762    .279741     0.03   0.978     .5847648    1.736249 
    Hospital |   2.213671   .5714403     3.08   0.002     1.334697      3.6715 
    _IN1S3_2 |   1.415428    .353189     1.39   0.164     .8679388    2.308269 
    _IN1S3_3 |   2.117652   .6183699     2.57   0.010     1.194807    3.753287 
         ECS |    2.57004   .7989712     3.04   0.002     1.397395    4.726726 
    nod_marg |   1.738441   .3929111     2.45   0.014     1.116289    2.707341 
         age |   1.011313   .0093548     1.22   0.224     .9931429    1.029815 
 
The next model removed age and included radiotherapy dose. Radiotherapy dose was 
not linear and multiple transformations were performed with the best approximation 
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being with a radiotherapy dose squared transformation shown below. The smoothed 
martingale residual plots are shown in the model diagnostics section. 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.057938   1.190459     2.87   0.004     1.425787     6.55847 
         xrt |    1.17696   .4704902     0.41   0.684     .5376421    2.576498 
    Hospital |   2.162151   .6119024     2.72   0.006     1.241625    3.765142 
    _IN1S3_2 |   1.371341   .3404308     1.27   0.203     .8430197    2.230763 
    _IN1S3_3 |   2.029183   .5897605     2.43   0.015     1.147965    3.586856 
         ECS |   2.616381   .8121525     3.10   0.002     1.423898    4.807541 
    nod_marg |   1.821799   .4092554     2.67   0.008     1.172961    2.829551 
     maxRTsq |   .9999303   .0001118    -0.62   0.533     .9997113    1.000149 
------------------------------------------------------------------------------ 
 
The introduction of radiotherapy dose to the model did not contribute significantly to 
the model or alter the other variable coefficients so it was removed. The next step was 
introduction of any clinically reasonable interaction terms. Since several prior 
publications from Westmead hospital had demonstrated a clinically and statistically 
significant effect of radiotherapy on survival, the most plausible interaction would be 
between the treating institution and radiotherapy. The model shown below 
demonstrates that both radiotherapy and the interaction term were significant, 
however the treating institution was no longer significant. This clearly showed how 
incorrect conclusions can be reached without consideration of potential interactions. 
The appropriate interpretation is not that outcomes at one institution are superior to 
the other (as the model above would suggest), however differences associated with 
radiotherapy administration between hospitals altered survival. Whilst it is not 
possible to determine what these differences are with the existing data I think it is 
likely this represents differences in treatment philosophies where in one institution 
radiotherapy is almost universally administered and in the other a more risk-adjusted 
approach is used. This means that in one hospital only patients who refuse or are too 
sick to receive radiotherapy are spared (hence the beneficial effect is exaggerated) and 
in the other institution only patients with more adverse features are given radiotherapy 
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(hence the beneficial effect is under-estimated). The adjusted effect of radiotherapy 
now estimates a 66% reduction in risk of death from cSCC with the administration of 
radiotherapy. Radiotherapy dose was reintroduced to the model but again was not 
significant. 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.292301    1.29014     3.04   0.002     1.527366    7.096696 
     _Ixrt_1 |   .3368084   .1266004    -2.90   0.004     .1612245    .7036144 
_IHospital_2 |   .6374435   .2885656    -0.99   0.320     .2624881     1.54801 
_IxrtXHos_~2 |   5.408739   2.822376     3.23   0.001      1.94502     15.0407 
    _IN1S3_2 |   1.411957   .3528379     1.38   0.167     .8651913    2.304255 
    _IN1S3_3 |   2.079099   .6048128     2.52   0.012       1.1756    3.676977 
         ECS |   2.771659   .8625334     3.28   0.001      1.50608    5.100722 
    nod_marg |   2.009846   .4558626     3.08   0.002      1.28854     3.13493 
------------------------------------------------------------------------------ 
 
The unexpected interaction between hospital and radiotherapy raise the likelihood that 
there may be a random effect or dependence among patients (clustering) within a 
hospital. As a result shared-frailty, correlated-frailty and stratified models were 
considered as shown below. Whilst clustering models are usually applied to 
multivariate survival data with repeated events for individuals it can be applied 
whenever failures times are correlated.  
Standard model 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.292301    1.29014     3.04   0.002     1.527366    7.096696 
     _Ixrt_1 |   .3368084   .1266004    -2.90   0.004     .1612245    .7036144 
_IHospital_2 |   .6374435   .2885656    -0.99   0.320     .2624881     1.54801 
_IxrtXHos_~2 |   5.408739   2.822376     3.23   0.001      1.94502     15.0407 
    _IN1S3_2 |   1.411957   .3528379     1.38   0.167     .8651913    2.304255 
    _IN1S3_3 |   2.079099   .6048128     2.52   0.012       1.1756    3.676977 
         ECS |   2.771659   .8625334     3.28   0.001      1.50608    5.100722 
    nod_marg |   2.009846   .4558626     3.08   0.002      1.28854     3.13493 
------------------------------------------------------------------------------ 
 
Shared frailty model 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.292301    1.29014     3.04   0.002     1.527366    7.096696 
     _Ixrt_1 |   .3368084   .1266004    -2.90   0.004     .1612245    .7036144 
_IHospital_2 |   .6374435   .2885656    -0.99   0.320     .2624881     1.54801 
_IxrtXHos_~2 |   5.408739   2.822376     3.23   0.001      1.94502     15.0407 
    _IN1S3_2 |   1.411957   .3528379     1.38   0.167     .8651913    2.304255 
    _IN1S3_3 |   2.079099   .6048128     2.52   0.012       1.1756    3.676977 
         ECS |   2.771659   .8625334     3.28   0.001      1.50608    5.100722 
    nod_marg |   2.009846   .4558626     3.08   0.002      1.28854     3.13493 
-------------+---------------------------------------------------------------- 
       theta |   2.11e-16   7.85e-13 
------------------------------------------------------------------------------ 
Likelihood-ratio test of theta=0: chibar2(01) =  1.5e-09 Prob>=chibar2 = 0.500 
47 
 
 
Stratified model 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.318109   1.307843     3.04   0.002     1.532452    7.184464 
     _Ixrt_1 |   .3407206    .128081    -2.86   0.004     .1630878    .7118283 
_IHospital_2 |  (omitted) 
_IxrtXHos_~2 |   5.287743    2.76028     3.19   0.001     1.900774    14.70991 
    _IN1S3_2 |   1.408486   .3519329     1.37   0.170     .8631095     2.29847 
    _IN1S3_3 |   2.068144   .6021529     2.50   0.013     1.168822    3.659429 
         ECS |   2.723583   .8471455     3.22   0.001     1.480411    5.010708 
    nod_marg |   2.012249   .4569151     3.08   0.002     1.289443     3.14023 
------------------------------------------------------------------------------ 
                                                        Stratified by Hospital 
 
 Correlated –frailty model 
                               (Std. Err. adjusted for 2 clusters in Hospital) 
------------------------------------------------------------------------------ 
             |               Robust 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.292301   .0438303    89.51   0.000     3.207507    3.379338 
     _Ixrt_1 |   .3368084   .0120704   -30.37   0.000     .3139625    .3613167 
_IHospital_2 |   .6374435   .0298987    -9.60   0.000      .581456    .6988219 
_IxrtXHos_~2 |   5.408739    .103622    88.11   0.000      5.20941    5.615696 
    _IN1S3_2 |   1.411957   .1134184     4.29   0.000     1.206276    1.652707 
    _IN1S3_3 |   2.079099   .0559756    27.19   0.000     1.972234    2.191756 
         ECS |   2.771659   .4475095     6.31   0.000     2.019788    3.803418 
    nod_marg |   2.009846   .1558786     9.00   0.000     1.726417    2.339806 
------------------------------------------------------------------------------ 
 
Within all of the preliminary and final models the coefficients remain stable, 
particularly with respect to the N1S3 and AJCC staging systems indicating that the 
estimates are reliable with the data available. The clustered model had smaller 
standard errors than the unclustered models due to negative correlation of residuals. 
Whilst all of the models seem reasonable and do not alter the final results, the 
correlated frailty model was used to account for a likely dependence among patients 
within each institution. This is because patients are nested within hospitals and cannot 
be assumed to be independent. 
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Model Diagnostics 
 
Test of proportional-hazards assumption 
N1S3 Model 
     ---------------------------------------------------------------- 
                  |       rho            chi2       df       Prob>chi2 
      ------------+--------------------------------------------------- 
      imm         |      0.09172         0.78        1         0.3783 
      _Ixrt_1     |     -0.09893         0.91        1         0.3396 
      _IHospital_2|     -0.16098         2.31        1         0.1287 
      _IxrtXHos_~2|      0.16177         2.49        1         0.1143 
      _IN1S3_2    |     -0.07582         0.55        1         0.4575 
      _IN1S3_3    |     -0.10308         0.95        1         0.3290 
      ECS         |     -0.02249         0.05        1         0.8285 
      nod_marg    |     -0.02848         0.07        1         0.7884 
      ------------+--------------------------------------------------- 
      global test |                      5.06        8         0.7509 
      ---------------------------------------------------------------- 
AJCC Model 
      ---------------------------------------------------------------- 
                  |       rho            chi2       df       Prob>chi2 
      ------------+--------------------------------------------------- 
      imm         |      0.09478         0.85        1         0.3573 
      _Ixrt_1     |     -0.09291         0.80        1         0.3723 
      _IHospital_2|     -0.13985         1.81        1         0.1788 
      _IxrtXHos_~2|      0.15097         2.24        1         0.1347 
      _ITNM_2     |     -0.02698         0.07        1         0.7933 
      _ITNM_3     |     -0.08842         0.75        1         0.3860 
      _ITNM_4     |     -0.03920         0.13        1         0.7162 
      _ITNM_5     |     -0.09188         0.77        1         0.3809 
      ECS         |     -0.02371         0.05        1         0.8183 
      nod_marg    |     -0.02992         0.08        1         0.7812 
      ------------+--------------------------------------------------- 
      global test |                      5.08       10         0.8855 
      ---------------------------------------------------------------- 
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Identification of influential outliers using Schoenfeld residuals 
 
 
 
 
 
 
 
Outliers 05/0703 / 04/1369 / 05/0723 / 96/1099 / 89/0954 / 87/0436 / 97/0270 / 
005388 / 003128 / 002984 / 000098 / 003457 / 002981 / 003354 / 003373 / 001341 / 
001669 / 001600 were identified and their files extracted to confirm survival status 
and clinicopathological variables. All data was confirmed to be correct and no 
patients were excluded. 
  
96/123107/2905
06/0409
91/1985
89/011787/0243
09/0702
96/018587/153498/0753 94/036400/1483
93/0373
97/164604/0010 96/17097/0 2798/0882 03/028801/0932 97/006098/136301/0707 05/1354
96/09896/080896/ 697
05/0002
96/019299/054796/0281
99/ 11
03/100391/0256
7/2011
99/1278
/1348
97/1591
95/ 155
98/1022
2/ 4 8 95/04900 / 4259/09 94 2 1 94/2038/ 591 910
/ 5 0
6
06/1266
91/153200/1 4
93/1279
07/0061
95/ 738/0 0396/11366/ 73
90/1749
87/1817
99/0685
90/063402/1454
07/0456
89/ 354
05/0723
91/1081
00 12
9/287/ 875
80/0276
92/0765
2 7 4
84/0942
01/0049
86/1329
9 1 01/0113
85/1718
85/1495
94/0 53
9 /1419 91/051803 0 5
95/ 5538 0 26
57
81/0356
/25 9
85/0497
0 10
97/1225
05/0703
4
3/ 123
6
91/0640
02/ 0895/1 879 0
89/1 8
99/091597/02 4
91/1782
88/0083
0 /29
/ 125
4/211903/ 13 01/042304/ 5 48/ 212 87/11962/ 4 .1
08/0408
7 07 88/0 39
0 3/
0 / 4 66/ 38
87/118
87/157
06 4 3 90/192891/0812
0 16 4/ 7206/ 2 04/02664 6 05/ 53 / 710/ 23/ 7
88/1380/ 6
89/1993
93/085892/1448 8 /1341/ 3 90/0 18
04/1369
4/ 331
/ 7 1 0 / 1 3/ 154/3 0 /0406/ 41 90/0389
89/0053
5/ 91
95/1099
3 73/ 61553
89/03537/ 620/ 8 1
2 0520
0 86/0732
90/ 597
85/1249
96/0136
02 09922 6
93/1996
97/0270
97/ 20
2/ 8
2
01/1426
6 0 820 /2 0 432/ 437/ 7
86/019301/ 55
02/0976
7/ 65 96/038306/ 38
9 16997/ 73
89/02416/038
6 5 3
096/17 / 96
3/12 2 6/11205/ 3 598/15580 2 6
8 5
04 0640
/ 1 9/ 696 17845 96 6 5
4/12 7
9 1 94/2 15
01/ 617
9 / 3309 49
81/0568
9 17 8
08/ 598/0223 65
0 3
878
5/ 83/141/ 9/ 3 99 /12 6 5227 4
83/0614
/ 1 27
93/ 62
97/1069
90/1460
2 6
96/1099
/0 6
89/0 54
4
4 8/1 878
8 /1232
3/ 2
87/0436
9/04955/138516 96/0913
85/0656
98/073906/0 4
2/ 255
1502/ 40
9 479 2 09 43
99/1531
9 3 0
85/ 7 2
5/
5/12 0
54
3/1 32
8
92/12116
7/ 460
1 23 2/1 2
3 107
4/15
8 1 06
1 18
8 / 09058
0 / 1
02/0 03
04/16/ 5 4 99
87/ 776
8
87/1 4
0
98/ 4911/ 3 7
3/ / 78 2
02/ 22297 1 48
3 474/ 4 /
126
2 1421
1373
/24 2
01/06 7
97/1620
00/ 023
24
0 2506
001600
8 8 00026092 577 6 86 005533 0025889 1 4046722 44 3 31 10 9
82 6 003330033 4 04428 0 05755 146 2 5 651340 8 7
002618
4 1
725003527
3259 77
03 2
2699 89
475 0 0016231 41 0029826 3270 63102099
0 0 8 00 4 57 6386 005550
53 3
55
71
145
00345
45 6 6
0016 9
69 2 9
1113
8229002 5
0 3 713 9 0 014376 889 25595 35 0 36 700 8
001340 3373
3 915 108 2
3037 236 7759 00 5898 29 07
53 2
331 9 100538 488 90 64 395 23 8 0032232 3
0 46003156
0 9836 6 21
0 03 8
0298
53106 8 43 96 3 58 4 37323 9 0 67 59
0 57 4
6
534 12 4 5 0 9357632003979
00807
-.
1
5
-.
1
-.
0
5
0
.0
5
.1
s1
0 5 10 15 20
_t
96/123107/290506/0409
91/1985
89/0117
87/024309/0702 96/0185
87/1534
98/0753 94/036400/1483
93/0373
97/164604/0010 96/170797/0 27
98/0882 3/02881/09 2
97/006098/136301/0707 05/13596/09896/080896/ 6 7
05/0002
96/019299/054796/0281 99/ 11 03/1003
1/025
07/201199/1278
86/1348
97/15 195 15
95/ 556
98/1022
82/ 4 8 95/0490/ 4259/ 94 2 1 94/2 3894/15 1
1 910
05/0590
6
06/1266 91/1532
0 /1 4 93/12797 0 95/ 738/0 0396/1 366/ 73 90/1749 8 /1817
99/0685
90/063 02/145407/0456 89/ 354
05/072391/1081
00 12
9/2 087/1875
80/0276
92/0765
2 7 4 84/094201/0049
86/1329
9 10 1/ 1 3
09/1205
85/1718
85/1495
/0 3 9 /1419
91/05183 04 5 5/ 5538 0 26
057
81/0356
/25 9 5/0490 1 5
97/ 22
05/0703
4 3/ 126
91/0640
02/ 08
95/1487
9
89/1818
99/0915
97/02 4782 88/0083
08/29
80/0125
4/21 93/ 13 01/0423/ 42 2 87/11962/1 5 .4 8
8 75
88/ 390 3/
/ 4966/ 33887 18
87/1570
06 4 3 9 /1928
91/0812
1 16
04/0172
6/ 9 2 04/02666 05/15 0 / 7
10/ 9 23/ 7 88/1380/ 6/ 3 93/085892/1448 87/1341/ 3 18
04/1369
04/ 331
04/ 3/ 15/413 /046/ 41
90/0389
89/0053
5/ 9
95/10
3 1 7
03/1161
553
8 / 3537/ 620/
92/05 0
1 86/0732
90/1 97
85/1249
96/0136 02/09926
93/1996
97/0270
9 /0020
/ 8
2 01/14262 2 42/ 437 7 86/01931/ 5
02/0976
7/065 96/03 3/1 38
1/1697 73
89/02416/0386
/ 196/17 8 / 8 96 3/12 2 6/1 2/ 3 5
98/15580 2 6 8 65
4 64
04/0109
/ 69 78 0845
96/0665
/12 79 94/2 15
01/ 617
99/1330 49 81/0568
90 1708
8/ 5038/ 23 88 75 2 329
01/0 78
95/
83/1411
09/0309
/ 6 227 4/ 83/06145/ 1 27
93/1362
7/ 6 90/1460
2
96/1099
0 6
89/ 954
4/1 8/ 1 8718
88/1232
3/ 2
87/0436
9/04955/1385/16 96/0913
85/0656
9 /07/
92/125
1502/ 479 / 2 08 4
99/1531
9 3 0 5 07
5/
/
85/ 3/ 38 92/12 16
07/ 46
23
02/1222
3 107
06/ 790 / 5 6
08/ 5
1 18 8 /0090580 /0 / 04/ 6
/15 4
8 99
87/1776
8
87/1 43
0
98/0491
91/0397
3/ /8 02/ 222
97/1148
3
4
4/ 4 26 5 26
2 1421 3706309/2
01/0667
97/1620
0 /0 23
002446
7 6
002250
06046
001600
04 260092348
000260
07983
0 6
2
005957
1 67 6
004386
008120
005533
002588
003085
001 14
004672
5 5614
003244
4
4353
4
001128
004459
4 9
9
003018
002776
001789
0 333
003354
04428
001057
005515
005414
006426
005666
0045
84 40 0 8
002618
4
0 8
000 054
001725
003527
004320
8 5309
0
7033
003128
2699
0 6789
001514
0 7635
492 8671
004351
5
001623
006641
51
002982
6
003277
006316
4 4
002099
000368
001405
7716
0 58 3
08
005550
5303
55
0 7083
1171
00014
858
003457
05632
002450
003100
001295
61 6
4 7
31 73 4
001669
00 605
3291
003249
001113
0 2 3
004352
0 9002
002056
0 5
003371
007389
0 143706 30 0 4889
002559
0 053
5953
931
0
36 7
005415
3 4
00 89
00134
0 3602
0 3373
03 59
0 1
006010
08 72
00234
003731
008347
003792
3
000435
000775
841
8
4 9
000589
2896
0076 0
02980
3097
5392
003433
10 2 53
5 82
01107
005388
048
15 8
0 1093
001795
0880
00098
003164
395
0 6102
3 8
003223
01801
00 2
0 835
0 46 0
003156
02983
7
68 6
001514
0 85 8
5
002425
4142
005727
7 61
001534
0441
000338
6
00298
0 5315
6
3 93
2 84
6385
004329
6
003255
06558
0 4049 0 37323297
6 8
001065
1
1 43
8905
8
0 1026
005734
003372008 37
0 9171
000667
7
008456
4953
23
3 518674
0 2 74
0016 1
8
00 935
0 785 71
00 829
87
005 86 632
003979
807
-.
0
6
-.
0
4
-.
0
2
0
.0
2
.0
4
s
2
0 5 10 15 20
_t
96/1231
07/2905
06/0409
91/1985
89/0117
87/024309/0702 96/0185
87/1534
98/0753
94/0364
00/1483
93/0373
97/1646
04/0010
96/1707
97/0 27
98/0882
03/0288
01/0932
97/006098/1363
01/0707
05/1354
96/09896/0808
96/0697
05/0002
96/0192
99/0547
96/0281
99/ 11
03/100391/025607/201199/ 278
8 /1348
97/1591
95/115/05 6
98/1022
82/0408
95/049006/0425
09/091094/2081
94/2038
94/1591
1 910
05/0590
/ 6
06/1266
91/1532
00/1 84
93/1279
07/0061
95/1738
0 /0 03
96/1136
06/ 673 90/1749
87/1817
99/0685
90/0634
02/1454
07/045 89/ 354
05/0723
91/1081
00 1209/22187/1875
80/0276
92/0765
2 4
84/0942
01/0049
86/1329
9/1011
01/0113
1205
85/1718
85/1495
94/0 53
9 /1419
91/0518
03 04 5
95/ 5538 0 261 057/ 3569/2509
85/0497
0 10 5
97/1225
05/0703
/0284
3/ 123
00 860
91/0640
02/ 08
95/1487
89/ 18
99/0915
97/02 4
91/1782
88/0083
08/2907
80/0125
94/2119
03/ 13 01/0423
04/ 5 4
0 /0212
87/1196
2/145 .1
08/0408
08/7507
88/0 39
03 3/
06/14966/1338
87/118
87/1570
06 423
90/1928
91/0812
1 16
04/0172
06/ 992 04/0266
4 6
05/1530 / 87
10/ 9 23/ 7
88/1380
9 / 608
89/1993
93/0858
92/1448
87/1341
/ 379
0/0 18
04/1369
04/ 31/ 7 1
04/ 83
4/ 01504/10 0
4 20
08 13
0 /048
6/0416 90/0389
89/ 05305/ 91
95/1099
3 7
03/ 161
553 89/0353
7/ 620
0 /18 1
92/ 5 0
0
86/0732
90/1597
85/1249
96/0136
02/09922 1166
93/19966 960
97/0270
9 / 20 2/ 82 4
01/1426
6 0182
/2
43
02/043
7/ 7
86/0193
/ 5
02/0976
07/0 10
5 8
96/0383
06/ 338
1/1699
73
89/0241
6/038
6 5 3
0
0 /27 096/17
8 / 889
1 6 3/12 2
6/11205/ 3 5
98/1558
0 2 6/
8 65
04 0640
04/0109
/ 696 1799
86 0845
96/0665
04/12 7
1 119
94/2 15
01/ 617
99/1330
9 49 81/0568
9 /1708
08/15
98/ 229
23
88 076
5/0556
2 329
9 /0 8
95/ 339 83/14117/ 5
09/1 9
/ 3 9
9 /128606/1522
7 5 5
83/0614
5/ 4
1 27
/ 3 2
97/1069
90/1460
02 68
96/1099
04/0 6
89/0954
90/1124
4 8
/ 9 8
6/ 211
871
/ 8 6
88/1232
03/ 2
87/0436
99/0495
5/1385
/16 6
96/0913
8 / 6
98/0739
06/02 4
92/ 5
154
02/1240
947
9 /0243
0
98 743
99/1531
3 5/ 7425/ 5/12 0
99/ 854
/1 32
/ 38
92/1211
6/0 6
1 0 23
02/1222
3 107
9
4/153
08/ 50
1 18
83/0090
9 58
/ 9
102/0703
04/16
/ 5 4 4/ 08
8 799
87/1776
48
87/1143
7 76
98/0491
91/0397
9 832
8/ 4
/0 7
2 02/ 222
7/11 8
3 9
4
7 454
4/ 442
6/ 5
26
2 1421
0 1370/1670
9 3
09/2402
01/0667
97/1620
00/0023
0024460 7 65
002250
1350
06 4
001600
0 48260 23480
000260
07 8
7 662
005957
9
47 6
004386
008120
005533
002588
4
003085
001914
0 27
614
03 44
4 3
4353
14
01128
0 44 9
0024
9
003018
02 76
001789
00333
003354
04428
001057005515
005414
64 6
6
004513
8 90 8 7
002618
4
0 8
1
548 7
00 725
003527
004320
0 4530 9 7
0 166
7 3
003128
2699
6789
01514
0 763530
671
04351
20
001623
006641
002982
6 4
003277
006316
02099
368
001405
710 5 3
004086
005550
5303
55
0 0
001171
00014
58
003457
6 2
002450
003100
01295
61 6
4 71
7003 4
01669
0 4605
03291
003249
01113
0 822
009 02
002056
003371
007389
0 0143
72
230
0 4889
002559
0 53
5953
3 3
36 7
0054 5
34 4
000890
0 1341
036
0 3373
03 59
11
006010
008972
0 2343
03731
008347
003792
36
435
0 9
00 775
84
04492
000589
2896
7
02980
0 97
5
03433
1 927564
9
82
01107
005388
048
15 8
093
001795
0880
0 098
02303 64
3 54
0 6102
3 8
003223
001801
005
0 835
0 4670
003156
2983
6 16
0 1514
85 8
6
002425
04142
005727
71
001534
4410 0338
002981
530 1506
6
3 93
02984
6 85
004329
6
003255
1 1
006558
0 4049 0 3732
32 7
6 08
001 6
1 9 4
9
5 9
089 5
001026
005734
00337
008037
0 7
0 6677
008456
4953
84 3
03451
04 67
2 74
001651
8
00 935
0 785
71
0 4
05829
87
0 286
632
003979
8 7
-.
0
4
-.
0
2
0
.0
2
.0
4
s
3
0 5 10 15 20
_t
96/1231
07/2905
06/040991/1985
89/0117
87/024309/0702 96/0185
87/1534
/0753 94/036400/1483
93/0373
97/1646
04/0010
96/170
97/0 2798/0882 03/0288
01/09 2
97/006098/1363
01/0707
05/13596/09896/0808
96/0697
05/0002
96/0192
99/054796/028 99/ 11
03/1003
91/025607/2011
99/1278
8 /1348
97/1591
95/1155 6
98/1022
82/0408
95/049006/0425
09/091094/2 81
94/2038
94/1591
1 910
05/0590
/ 306
06/1266
91/1532
00/1 84 93/1279
07/0061
95/1738
/0 03
96/1136
06/ 673
90/1749
87/1817
99/0685
90/0634
02/1454
07/0456
89/1354
05/0723
91/1081
00 12
09/221087/ 875
80/0276
92/0765
2/ 7 4 84/0942
01/0049
86/ 3299/10
01/0113
1205
85/1718
85/1495
94/0 53
9 /1419
91/0518
3 04 5
95/ 553
8 0926
057
81/0356
/25 9 5/0490 1 5
97/1225
05/0703
/ 284 3/ 1236
91/0640
02/ 08
95/1487
9
89/1818
99/0915
97/02 491/ 782
88/0083
08/2907
80/0125
94/2119
03/ 13 01/042304/ 4/02
87/1196
2/145 .1
8/ 408
08/7507
88/0 39
0 3/
06/14966/ 338
87/1189
87/1570
06 423
9 /1928
91/0812
1 16
04/01726/ 9 2 04/0266
6
05/153 / 87
10/ 23/ 7 88/1380
9 / 608
/ 93
93/0858
92/1448
87/1341
/ 379
0/0 18
04/1369
04/1331
09/2711
04/ 83
/ 1504/1
4 20
08 13
0 /048
6/ 4
90/0389
89/0053
5/ 9
95/1099
3 73/ 161
5583 7
89/0353
7/ 620
08/1801
92/05 0
0
86/0732
90/1 97
85/1249
96/0136
02/0992
1166
93/1996
06/0960
97/0270
97/002
02/0118
2
01/1426
6 0182
08/2110
43
2/ 437 7 86/0193
01/ 455
02/0976
7/05 8
96/03 3/ 38
1/ 699
7/ 73
89/0241
6/038
6/ 593
0
9/ 1096/17
8 / 889
6
3/1212
6/1 205/ 3 5
98/15580 2 69/1811
8 65
04 0640
04/0109
/ 696 7 9
86 0845
6/ 665/12 719 /0
94/2 15
01/ 617
99/1330
9 49 81/0568
9 1708
08/15
98/0229
23
88 076
/ 5 27
01/08 8
95/ 339 83/1 117 5 912
06/15227 4
0 / 05 83/0614
5/ 4
1 27
93/1362
97/1069
90/1460
02 68
96/1099
/ 6
89/0954
/ 24 4 8
/ 9 8
6/ 211 8718 8 88/12323/ 2
87/0436
9/0495
5/1385
/16 6
96/0913
85/0656
98/0739
6/
92/1255
154
2/129 47
96/02 3
098 74
99/1531
9 3 0
85/ 742
5
5 12 0
9 / 854
03/1132
/ 38
92/12 1
6 1
07/0460
1 23 /3 1070 4/15
08/ 06
1 18 83/0090
58
00/1369
102/0703
04/16
9/ 5 4 4
8 799
87/1776
8
87/1143
7 76
98/0491
9 / 397
9 832
08/
/ 7
80 0022
02/0222
97/1148
3 9
4
74/ 4 2
6/ 5
2
2 1421
0 1370/16709 3
09/2402
01/0667
97/1620
00/0023
002446
8
002250
3
006 4
001600
40080
000260
07983
74662
0 957
019 6766 43868 2
33
002588
4
003085
001914
004672
4 32444 3 530 9
0024 9
30 8
0 7761 9
00333
003354
04428
001057
5 15
05414
006426
005666
004513
40 857
002618
4
0 8
1
0 005
00 72
0 35 7
43
0 4537
7 3
003128
02699 8915 49 67
004351
520
001623
006641
002982
6
003277
00 316
0 2099
000368
01 05
007716
004086 005550
5303
55
01 7
00014
5
003457
6 2
002450
31 0
0 5
61 631 7
003 4
001669
00 6 5
03291
003249
001113
2
04352
009002
002056
003371
007389
0 0143
007294
2 0 4889
02559
3
5953
3 36 7
0 415
034
89
0 134
6 2
003373
0 3 59
0015118972 02343
0 7 1083
037 2
3 40 3 9
000775
84
04492
000589
2896
007640
029807
5392
33
1275
01107
005388
0 480
15 8
90 7 5
00 80
0 098
0 3 64
0 3954
61 23 8
003223
001801
0 0 8
00467003 56
9
002983
5
6 16
0 1514
05 54
6
002425
2
005727
71
001534
441
000338
002981
0 531506
9
0029 4
0 6385
004329
6
003255
3
0 65 8
4049 0 3732
3297
001 65
1 9
4
0 4985
9588
0 10 6
005734
003372
7
0 9171
000667
7
008456
950
03451
8674
0 2 7
1 416
00 935
852
71
078 98
00 86
63
0
008075
-.
0
4
-.
0
2
0
.0
2
.0
4
s
4
0 5 10 15 20
_t
96/123107/2905
06/040991/1985
89/011787/0243
09/070 96/018587/153498/0753
94/0364
00/1483
93/0373
97/164604/0010 96/17097/0 27
98/0882
03/028801/0932
97/006098/136301/0707
05/1354
96/09896/080896/0697
05/0002 96/0192
99/054796/0281 99/ 11 03/100391/0256
07/2011
99/1278/1348 97/159195/1155 98/10222/ 4 8 95/04900 / 425
9/
94/2081
94/203894/15 1
1 910
05/0590
0 /2306
06/1266
91/1532
0 /1 4 93/12797/ 06
95/1738
/0 0396/1136
06/ 673 90/1749
87/1817
99/0685
0/063402/1454
07/045
89/ 354
05/0723
91/1081
00 129/2 187/1875
80/0276
92/0765
2 4 84/0942
01/004986/1329
9 10
01/0113
85/1718
85/1495
94/0 53
9 /1419
91/0518
3 04 5 95/ 5538 0 26
1 0 70/ 3 6/2509 85/04970 1 5
97/ 225 05/0703
/0 84
3/ 12361/ 4 02/ 08
9 1487
98 8 9 /09 57/ 2 4
782 88/00830 /29
80/0125
94/211903/ 13 01/042304/05 4/ 2 2 87/119602/145 .
/ 4 8
08/75 7
88/0 390 3/
06/1496
6/ 887/11
87/1570
06 4 3
90/192891/0812
16 4/ 7206/ 2
04/0266
4 6
05/153 1/ 87
10/ 9 23/ 7 88/1380/ 6
/ 3
93/085892/1448
87/1341
/ 3790/0 18
04/ 36904/ 31
04/ 83/ 15/14 23 0 /040 /0 16
90/0389
89/0053
5/ 9
95/1099
3 73/ 1
553 89/03537/ 620/ 1
92/05 0
0
86/073290/1597
85/1249
96/ 36
2 992
6 93/1996
97/0270
9 / 0 0 2/ 82 1/ 426
6 0 82
2
432/ 43
7 7 86/0193
/ 5
02/0976
07/0 15
96/0383
/1 38
1/1699
3
89/0241
6/0386 5 3/96/17 8 / 9
6 3/12 2 6/11205/ 3 5
98/1558
0 2 6 8 65
04 64
4/0109
/ 617 986 0845
96/0665
/ 2 79 94/2 15
01/ 617
99/1330
9 49 81/0568
9 1708
08/ 598/0223 8 07
56 329
09 711/0 895/ 3
83/1411
09/ 3 9
/ 8
06/1522
7
09/15 83/0614
5/ 1 27
3 27/1 69 90/1460
02 8
96/1099
4/0 6
89/0954
4 8/ 8/ 871
08/ 8 6
8 /1232
3/ 2
87/0436
9/0495
5/1385
16
96/0913
8 /
98/073
06/02 4
92/1 5 154
02/1240
479 2 08 43
99/1531
3 5/ 7 25/ 5/12 0
/ 854
/1 3
/ 388
92/12116 23
0 /12 2
3 107
4/153
08/1506
1 18
83/0090
9 58
9
13 04/16
/ 5 4
4 08
8 99
87/1776
8
87/1143
0 7
98/0491
9 0 97
8 3
8/ 4
/0 17
02/ 22297/1 483 9
47
4/ 46/ 5 26
2
00 13704/167
309/2
01/0667
97/1620
00/0023
4 6
002250
35
06 4
001600
04 269 4
00026007983
0 7 62
59 7
19
7 6
0 4386
8120
005533
002588
3
003085
19 44672
61
3244
4 3
4 53
0 1
001128
0 440 24 9
29
003018
002776
1789
333
003354
442
001057
005515
0541
0 6426
00566651
8 90 8
002618
4
60 811000
8
001725
0 3527
04320
0 84537
01 6
0 3
003128
2699
0 6 89
001514
67
04351
2
001623
006641
5
0 2982
6
03277
00631
02099
8
001405
7716
58 3
8
005550
5303
55
0 7 83
01 71
0 14
5
003457
5632
2450 003100129
1 6
7
1
3 4
001669
04605
3291
249
001113
0 82
0 352
009002
002056
4
003371
0 7389
00 3007294
2
0 48
002559
0 53
5953
0
5 04
36 7
05415
0 34
890
0013410 3373
355
00151
0 10
08972
02343
0 3 31
8 7
7 2
3
0 35
29
00 75
8
04492
0 589
2896
7640
0298
30 7
5392
33
1
027 45
0 5 2
01107
005388
0048
001 8179 08 0
000098
02003 6
0 3954
0 6 2
3 8
00322318 1 35
0 467003156
2
002983
7
6 16
0 1 14
0 5 3
2425
41 2
7
1
001534
441
00 338
6
5
002981
0 31506
61
93
2984
6385
0 4329
6
03255
1
6 8
04 49 0 3732
3297
0 6 08
001065
1
1 43
4 85
9
008905
005734
337
80 71
000667
7
008456
4953
4 3
3 51
8 7
422 4
0 1 51
0 35
7
71
2
5 29
7
05286
6 2
003979
807
-.
1
-.
0
5
0
.0
5
s
5
0 5 10 15 20
_t
96/1231
07/2905
06/0409
91/1985
89/0117
87/0243
09/0702
96/018587/153498/0753 94/0364
00/1483
93/0373
97/164604/0010 96/170797/0 27
98/0882
03/028801/0932
97/006098/1363
01/0707 05/1354
96/09896/0808
96/ 697
05/0002
96/01 2
99/0547
96/0281
99/ 11
03/1003
91/02567/2011
99/1278
86/1348 97/1591
95/115
95/0556
98/1022
82/04 8
95/04906/0425
09/ 094/2081
94/203894 59
1 910
05/0590
/ 66/1266
91/153200/1 84
93/1279
07/0061
95/1738/0 0396/1136
06/0673
90/174
87/1817
99/0685
90/0634 2/1454
07/0456
89/ 354
05/ 723
91/1081
00 12
9/2 108 /18 5
80/0276
92/0765
2 7 4
84/0942
01/0049
86/1329
9 1 1
01/011309/12 5
85/1718
85/1495
94/0 53
9 /1419 91/05180 04 5
95/ 5538 0 26
570
81/0356
/2509
85/0497
0 10 5
97/1225
05/0703
4
3/ 123
/ 6
91/0640
2/ 085 1487
9
89/1818
99/0915
97/02 4
/ 782
88/0083
08/29 7
80/0125
94/2119
03/ 13 01/042304/ 5 4
08/021 87/11962/145 .
8/04087
88/0 390 30 /
06/ 4 66/ 338
87/1189
87/1570
06 4 3
90/1928
91/0812
0 16
04/0172
06/ 2 0 / 2664 6
5/15301/ 87
1 / 9 23/ 7
88/1380
9 / 608
/ 3
93/0858
92/1448 87/1341
/ 379
0/0 18
0 /1 69
04/1331
0 / 7
04/ 83/ 154/1 0
08 3
0 /046/ 416
90/0389
89/0053
5/ 91
95/1099
3 7
03/1161
553
89/03537/ 620
8/ 8 1
92/0520
0 86/07 2
90/1597
85/1249
96/0 3
02/0 22 11 6
93/1996
9
97/0270
97/0020
2/ 8
2 4 1426
6 01808/2 0 43
2/ 43
7 7
86/019301/ 55
02/0976
07/0 10
5
96/038306/ 338
1/1699
7/ 73
9/0241
/0386 593
0 0
96/17
/ 889
6
/12 2 6/11205/ 3 5
8 558
0 2 6/
8 65
04 0640
04/0109
/ 696 1799
86 845
9 / 665
/ 2 7
1 19 0
94/2 15
01/ 617
9/ 0
9 49 81/0568
90/1708
0 /15 398/022
23
8 07
95/ 56
329
01/08 8
95/ 33
83/1411
/ 093 9
9 /12 6 6 522
7 4
/
83/0614
5/ 1 27
93/1362
97/1069
90/1460
02 68
6 9
04/0 6
89/0954
/ 4
4 8
/ 96 2 1
1
0 / 8 6
88/1232
3/ 12
87/0436
9/0495
5/ 85/16 96/0913
85/0656
8 73906/02 4
92/125
5402/1240
47
9 / 2 3
0
9 743
99/1531
9 3 0
8 / 7 2
5/
5/12 0
3/1 32
/ 88
92/12116 1
07/0460
1 0 23 / 2 2
3 107
4/1536
08/1506
18
83/00909 58
0 / 36
1
/ 3
4 1
0 5 4 04/1208
8 99
87/1776
8
87/1143
7
98/0491
91/0397
9 1830 / 4
/ 7
8 22
02/ 222
97/1148
3 9
4454
4 46/ 5
6
2 14 1
7/1
309/2402
01/0667
97/1620
0/ 023
002446
89007165
002250
7 353 6 6
001600
48 289248
000260
79832 0059570 19 6766
004386
008120
005533
002588
4
003085
001914
004672
545
3244
4 3
4 53
0 014
001128
00445902419
003018
776
001789
00333
003354
04428
001057
005515
005414
006426
005666
04513
0 8490 857
002618
4 0 0
0 1000054
8
001725
003527
004320
8 539 716
7 303 28
2699
89
01514
0 50 940 28 8 71
00435
520
001623006641
8 5
002982
6
003277
006316
4
002099
000368
001405
0 7716
086 005550
5303
55
0 7083
001171
00014
5
003457
5 32
0 450
003100
001295
61 6
13197
003 8
001669
004605
3291
0 3249
001113
8243
004352
009002
002056
5
003371
007389
0 01430 7
006230
0 4889
0025596053
5953
00931 36 7
05415
74
000890
001341
36 2
0 3373
3 9
001511
006010
08972
02343
003731
0083 7
0037929 36
000435
9 000775
841 04492
0005892896007640
02980
97
5392
0 3433193 53645 8
01107
0 538
048
1 8
0 0 3
001795
0880
000098
023 3 64
0 3954
0 6102
3
003223
001801
00 2
0 835
0 4670
003156
002983
0 57
68 6
0015 4
85 86 03
02425004142
005727
01534
0441
000338
0 8
002981
0 531506
0 1
93
2984
38 043 96
003255
0 6 58
0 4049 0 37320 3297
6 08
001065
911
4
5 09
0 8905
001026
005734
0 3 72
37
009171
000667
7 7
008456
4953
3
03451
8674
42 174
001651
7
00 935785
71
00 829
7
0 5286 632
003979
807
-.
0
4
-.
0
2
0
.0
2
.0
4
s
6
0 5 10 15 20
_t
50 
 
Assessment of linearity assumptions for staging variables using Martingale residuals 
 
N1S3      
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Radiotherapy dose (RTdose) and transformations 
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Assessment of Goodness of fit using Cox-Snell Residuals 
 
The unclustered models were first assessed 
 
N1S3 
Cox regression -- Efron method for ties 
No. of subjects =          602                     Number of obs   =       602 
No. of failures =           92 
Time at risk    =  1854.983286 
                                                   LR chi2(8)      =     50.95 
Log likelihood  =    -514.0584                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.292261   1.290122     3.04   0.002     1.527348    7.096602 
     _Ixrt_1 |   .3367946   .1265951    -2.90   0.004      .161218    .7035851 
_IHospital_2 |   .6374646   .2885748    -0.99   0.320      .262497     1.54806 
_IxrtXHos_~2 |   5.409894   2.823018     3.24   0.001     1.945407    15.04413 
    _IN1S3_2 |   1.411954   .3528384     1.38   0.167     .8651887    2.304255 
    _IN1S3_3 |   2.079538   .6049378     2.52   0.012     1.175851    3.677744 
         ECS |   2.771764   .8625684     3.28   0.001     1.506134    5.100923 
    nod_marg |   2.010123   .4559328     3.08   0.002     1.288708    3.135384 
------------------------------------------------------------------------------ 
Harrell's C concordance statistic 
 
  Number of subjects (N)              =      602 
  Number of comparison pairs (P)      =    34773 
  Number of orderings as expected (E) =    23964 
  Number of tied predictions (T)      =     1360 
 
          Harrell's C = (E + T/2) / P =    .7087 
                            Somers' D =    .4174 
 
 
AJCC 
Cox regression -- Efron method for ties 
No. of subjects =          602                     Number of obs   =       602 
No. of failures =           92 
Time at risk    =  1854.983286 
                                                   LR chi2(10)     =     50.48 
Log likelihood  =   -514.29409                     Prob > chi2     =    0.0000 
 
------------------------------------------------------------------------------ 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.320736    1.31152     3.04   0.002     1.531276     7.20137 
     _Ixrt_1 |   .3384321   .1281478    -2.86   0.004      .161125    .7108537 
_IHospital_2 |   .5898643   .2729426    -1.14   0.254     .2381679    1.460901 
_IxrtXHos_~2 |   5.628694   2.962251     3.28   0.001     2.006504    15.78975 
     _ITNM_2 |   1.120705   .4796412     0.27   0.790     .4843876    2.592925 
     _ITNM_3 |   1.593284   .3915728     1.90   0.058     .9842335    2.579221 
     _ITNM_4 |   1.420321   1.055898     0.47   0.637     .3308142    6.098018 
     _ITNM_5 |   2.166823   .8614827     1.94   0.052     .9940395    4.723273 
         ECS |   2.923738   .9016245     3.48   0.001     1.597513    5.350972 
    nod_marg |   1.983819   .4537287     3.00   0.003     1.267126    3.105878 
------------------------------------------------------------------------------ 
  Harrell's C concordance statistic 
 
  Number of subjects (N)              =      602 
  Number of comparison pairs (P)      =    34773 
  Number of orderings as expected (E) =    23833 
  Number of tied predictions (T)      =     1428 
 
          Harrell's C = (E + T/2) / P =    .7059 
                            Somers' D =    .4118 
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This was compared with the clustered models and the same results observed (only 
N1S3 model shown) 
 
N1S3 
Cox regression -- Efron method for ties 
No. of subjects      =          602                Number of obs   =       602 
No. of failures      =           92 
Time at risk         =  1854.983286 
                                                   Wald chi2(1)    =     39.89 
Log pseudolikelihood =    -514.0584                Prob > chi2     =    0.0000 
 
                               (Std. Err. adjusted for 2 clusters in Hospital) 
------------------------------------------------------------------------------ 
             |               Robust 
          _t | Haz. Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         imm |   3.292261   .0437341    89.70   0.000      3.20765    3.379104 
     _Ixrt_1 |   .0622553   .0034459   -50.16   0.000     .0558548    .0693892 
    Hospital |   .6374646   .0298748    -9.61   0.000     .5815198    .6987916 
_IxrtXHosp~1 |   5.409894   .1051462    86.86   0.000     5.207687    5.619952 
    _IN1S3_2 |   1.411954   .1134065     4.30   0.000     1.206294    1.652678 
    _IN1S3_3 |   2.079538    .056946    26.74   0.000     1.970869      2.1942 
         ECS |   2.771764   .4474134     6.32   0.000     2.020025    3.803257 
    nod_marg |   2.010123   .1564317     8.97   0.000      1.72576    2.341342 
------------------------------------------------------------------------------ 
 
  Harrell's C concordance statistic 
 
  Number of subjects (N)              =      602 
  Number of comparison pairs (P)      =    34773 
  Number of orderings as expected (E) =    23964 
  Number of tied predictions (T)      =     1360 
 
          Harrell's C = (E + T/2) / P =    .7087 
                            Somers' D =    .4174 
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Additional Lift curves 
 
COMBINED LIFT CURVES FOR PATIENTS DEAD OR SURVIVING GREATER THAN ONE YEAR 
 
 
COMBINED LIFT CURVES FOR PATIENTS DEAD OR SURVIVING GREATER THAN TWO YEARS 
 
 
COMBINED LIFT CURVES FOR PATIENTS DEAD OR SURVIVING GREATER THAN THREE YEARS 
 
 
COMBINED LIFT CURVES FOR PATIENTS DEAD OR SURVIVING GREATER THAN FIVE YEARS 
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